COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network.
Saved in:
| Title: | COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network. |
|---|---|
| Authors: | Laniece Delaunay, Charlotte1 (AUTHOR), Verdasca, Nuno2 (AUTHOR), Monge, Susana3 (AUTHOR), Domegan, Lisa4 (AUTHOR), Sève, Noémie5 (AUTHOR), Buda, Silke6 (AUTHOR), Meijer, Adam7 (AUTHOR), Lucaccioni, Héloïse1 (AUTHOR), López Torrijos, Miriam8 (AUTHOR), McKenna, Adele4 (AUTHOR), Enouf, Vincent9 (AUTHOR), Dürrwald, Ralf10 (AUTHOR), In't Velt, Eline7 (AUTHOR), de Valcárcel Laiglesia, Mª Ángel11 (AUTHOR), Bennett, Charlene12 (AUTHOR), Masse, Shirley13 (AUTHOR), Erdwiens, Annika6 (AUTHOR), Hooiveld, Mariette14 (AUTHOR), Mlinarić, Ivan15 (AUTHOR), Túri, Gergő16 (AUTHOR) |
| Source: | Influenza & Other Respiratory Viruses. May2025, Vol. 19 Issue 5, p1-5. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
